CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 14 enrolled
Drug / intervention
Mathematical Model-Adapted Radiation Fractionation Scheduleradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03557372
NCT03557372N/ACompleted
CompareCT.gov

Mathematical Model-Adapted Radiation Fractionation Schedule for Patients With Recurrent Glioblastoma (MARS-Glio)

Dana-Farber Cancer Institute·interventional·Posted Jun 15, 2018·Updated Oct 26, 2023

In Brief

A clinical study evaluating Mathematical Model-Adapted Radiation Fractionation Schedule for Recurrent Glioblastoma. Completed, enrolled 14 participants across 2 sites.

Detailed Summary

This research study is studying a new schedule of radiation therapy for recurrent glioblastoma as a possible treatment for this diagnosis. This radiation schedule is based on a new model for radiation resistance in glioblastoma. The name of the radiation schedule involved in this study is: \- Re-irradiation for glioblastoma using a novel Mathematical Model-Adapted Radiation Fractionation Schedule

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Glioblastoma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 15, 2018
Enrollment StartNov 12, 2018
Primary CompletionNov 9, 2022
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.0 years ago

Interventions

Mathematical Model-Adapted Radiation Fractionation Scheduleradiation

* Re-irradiation with 35 Gy delivered over 2 weeks, based upon reference dosing of 35 Gy in 10 Fractions over 2 weeks * Radiation therapy is delivered on Monday-Friday during standard clinic hours in our department. Each treatment may take 20-40 minutes. * Treatment will be once daily for the first 7 days of treatment and then three-times daily for the last three days of treatment.